Wells Fargo Maintains Overweight on NovoCure, Lowers Price Target to $49
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Larry Biegelsen has maintained an Overweight rating on NovoCure (NASDAQ:NVCR) but lowered the price target from $102 to $49.
August 29, 2023 | 2:02 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
NovoCure's price target has been lowered by Wells Fargo from $102 to $49, though the Overweight rating is maintained.
The lowering of the price target by a significant amount indicates a less optimistic outlook for the company's stock, which could lead to a decrease in its price in the short term. However, the maintenance of the Overweight rating suggests that the analyst still sees potential in the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100